Company intelligence / Profile preview

Marvel Systems

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

The lead compound MB‑204, a novel fluorinated derivative of the anti-Parkinson’s drug istradefylline (an A2A adenosine receptor antagonist), has shown strong efficacy in preclinical models for neurological and neurodevelopmental disorders. cGMP synthesis and toxicology studies are complete with IND-enabling studies underway. Recent data show significant promise in Rett syndrome models compared to trofinetide. No clinical results yet published.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculeSynthetic chemical derivative
Industry: Biotech

Partnerships

Zhejiang Ausun Pharmaceutical Co., Ltd. – cGMP manufacturing partner for API production of MB‑204

Beyond the preview

Go deeper on Marvel Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marvel Systems.

Explore the full profile